doi: 10.1161/hc4401.099447
(Circulation. 2001;104:2266.)
© 2001 American Heart Association, Inc.
Brief Rapid Communications |
Soluble CD40L and Cardiovascular Risk in Women
From the Leducq Center for Cardiovascular Research, Cardiovascular Medicine and the Center for Cardiovascular Disease Prevention, Brigham and Women’s Hospital and Harvard Medical School, Boston, Mass.
Correspondence to Uwe Schönbeck, Leducq Center for Cardiovascular Research, Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, 221 Longwood Ave, LMRC 309, Boston, MA 02115. E-mail uschoenbeck{at}rics.bwh.harvard.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— The immune-signaling dyad CD40/CD40L promotes atherogenesis, and patients with unstable angina have elevated plasma levels of soluble CD40L (sCD40L) and membrane-bound CD40L. It is unknown, however, whether elevations of circulating sCD40L precede the onset of acute cardiovascular symptoms.
Methods and Results— In a prospective, nested case-control evaluation of healthy middle-aged women, mean concentrations of sCD40L at baseline were significantly higher among 130 participants who subsequently developed myocardial infarction, stroke, or cardiovascular death (cases), compared with 130 age- and smoking-matched women who remained free of cardiovascular disease (controls) during a 4-year follow-up (2.86 ng/mL for cases versus 2.09 ng/mL for controls; P=0.02). Women with concentrations above the 95th percentile of the control distribution (>3.71 ng/mL) had a significantly increased relative risk (RR) of developing future cardiovascular events (RR, 3.3; 95% CI, 1.2 to 8.6; P=0.01) that remained after adjustment for usual cardiovascular risk factors (multivariate RR, 2.8; 95% CI, 0.9 to 8.0; P=0.05).
Conclusions— High plasma concentrations of sCD40L may be associated with increased vascular risk in apparently healthy women.
Key Words: atherosclerosis • immune system • risk factors
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Previously, we and others have demonstrated that the multipotent immunomodulator CD40L and its receptor CD40, expressed on vascular endothelial cells, smooth muscle cells, mononuclear phagocytes, and platelets, promote a wide array of pro-atherogenic functions in vitro.1–5 Ligation of CD40 on endothelial cells, smooth muscle cells, or mononuclear phagocytes triggers the expression of various proinflammatory mediators, such as the cytokines interleukin (IL)-1, IL-6, IL-12, tumor necrosis factor-
, and interferon-
; the chemokines IL-8, monocyte chemoattractant protein-1, and RANTES (regulated upon activation, normal T cell expressed and secreted); intercellular adhesion molecule (ICAM)-1 and vascular cell adhesion molecule (VCAM)-1; the matrix metalloproteinases-1, -2, -3, -7, -8, -9, -10, -11, -12, and -13 as well as the procoagulant tissue factor.5 These observations implicate CD40L in the various stages of atherogenesis, including the initiation and progression of atherosclerotic lesions as well as acute complications. In accord with the predicted role the CD40/CD40L dyad in atherogenesis, disruption of CD40 signaling significantly diminished lesion formation and progression in hypercholesterolemic mice.6 Interruption of CD40/CD40L interactions also prevented the progression of established atheroma and promoted processes associated with plaque stabilization in humans.7,8 These in vitro and in vivo studies identified CD40L as a potential therapeutic target for treatment of atherosclerosis, although the underlying mechanisms by which interruption of CD40 signaling affects atherogenesis require further investigation. In addition to the 39-kDa, cell-associated form, CD40L also occurs in a soluble, biologically fully active form (sCD40L).9 Interestingly, patients with unstable angina have higher concentrations of functional sCD40L than do patients with stable angina or healthy volunteers, possibly as a result of release from activated platelets or T lymphocytes (U. Schönbeck, PhD, et al, unpublished observations, 2001).10 It remains unknown, however, whether plasma concentrations of sCD40L also have diagnostic or prognostic value among apparently healthy individuals before the onset of acute cardiovascular events.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
We performed a prospective, nested case-control analysis among participants in the Women’s Health Study (WHS), an ongoing primary prevention trial evaluating the efficiency of vitamin E and low-dose aspirin in 28 263 middle-aged American women with no history of cardiovascular disease or cancer.11 Blood samples were collected in EDTA and stored in liquid nitrogen until analysis. For this study, 130 women who subsequently developed either nonfatal myocardial infarction or stroke or died from acute cardiovascular events during the initial 4-year follow-up period were selected as case subjects. A committee of physicians using standardized procedures classified end points. For each confirmed case, a control participant of the same age (±2 years) and similar smoking status (former, current, or never) who remained free of reported cardiovascular disease was selected.
Baseline plasma sCD40L concentrations were measured by ELISA (Bender MedSystems). Briefly, diluted (1:5) plasma samples were applied in triplicate to 96-well plates precoated with mouse anti-human CD40L antibody and mixed (1:2) with a horseradish-peroxidase–labeled secondary mouse anti-human CD40L antibody (2 hours). Subsequently, plates were washed and antibody binding determined by colorimetry using 3,3'-5,5'-tetramethylbenzidine substrate. Absorbance was read at 650 nm and plasma concentrations of sCD40L were determined by comparison with serial dilutions of recombinant human CD40L. Analysis was performed in a blinded fashion. Intra-assay variation among the triplicates for all samples was less than 15%. Lipid levels were measured in a laboratory that participates in the Centers for Disease Control standardization.
Means and proportions for baseline clinical characteristics of the study participants were computed and compared using either Student’s t test or the 
2 statistic. Relative risk (RR) of developing future cardiovascular events associated with increasing levels of sCD40L at baseline were then computed in a series of logistic regression analyses that divided the study sample according to the 50th, 75th, 90th, 95th, and 99th percentile cutpoints of the control distribution for sCD40L. All P values are 2-tailed and all confidence intervals are computed at the 95% level.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Table 1 shows the baseline clinical characteristics of the study participants. As expected, women who developed cardiovascular disease during follow-up were more likely at study entry to be obese, hypertensive, or diabetic, or to have a family history of premature atherosclerosis, compared with women who remained free of disease. LDL cholesterol and triglyceride levels were higher at baseline among cases, whereas HDL cholesterol levels were lower (all P
0.01). Use of hormone replacement therapy did not differ significantly between the 2 groups.
|
Overall, plasma levels of sCD40L at baseline among cases exceeded that in controls (2.86±0.35 versus 2.09±0.19 ng/mL; P0.02) (Table 1). This difference was almost entirely the result of an excess of particularly high values among the case subjects. The great majority of cases and control subjects had similar levels of sCD40L at study entry (Figure). However, 11 cases had baseline levels of sCD40L in excess of the 99th percentile cutpoint for the control distribution, compared with only 1 control subject (P0.01).
|
RRs for developing future cardiovascular events, according to the prespecified cutpoints defined by the distribution of the study controls, rose with increasing concentrations of sCD40L and became statistically significant with levels of sCD40L in excess of the 95th and 99th percentile cutpoints (RR: 3.29 [P0.02] and 11.83 [P0.01], respectively) (Table 2).
|
An additional post-hoc analysis was performed, comparing clinical characteristics among the 12 participants with levels of sCD40L in excess of the 99th percentile cutpoint with the 248 participants with lower levels. Age, smoking, body mass index, LDL and HDL cholesterol levels, and hormone replacement therapy were similar between these 2 study groups (Table 3). Study participants with particularly elevated levels of sCD40L had somewhat higher rates of hypertension and a family history of premature coronary artery disease, but neither of these differences achieved statistical significance. None of the 12 women with markedly elevated baseline levels of sCD40L had diabetes. Moreover, there were no significant differences in the time from randomization to the cardiovascular event between the 11 cases with extreme sCD40L levels and the remaining cases with lower sCD40L (15.9 versus 19.5 months; P=0.3). Assignment to aspirin versus placebo presumably did not affect our observation because within the group of 12 subjects showing the highest sCD40L concentrations, 6 were randomly assigned to aspirin and 6 to placebo. In addition, the blood samples assayed for sCD40L were drawn before randomization.
|
Previous reports on this cohort have documented an association of plasma levels of C-reactive protein, IL-6, serum amyloid A, and ICAM-1 with increased cardiovascular risk.12 However, we observed no significant correlation between these parameters and sCD40L.
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
In this prospective, nested case-control study of apparently healthy middle-aged women, markedly elevated plasma concentrations of sCD40L at baseline (>5.54 ng/mL) foretold a significantly increased risk of future cardiovascular events. Previous studies demonstrated that patients with unstable angina had significantly higher serum levels of sCD40L when compared with patients with stable angina and controls.10 In this circumstance, activated platelets or T lymphocytes may release sCD40L secondarily. The present study, however, demonstrates elevation of sCD40L concentrations in some women before events that may result from acute thrombosis.
Little is known regarding the mechanisms yielding release of soluble forms of CD40L. Potential sources for sCD40L in plasma include platelets and T lymphocytes, as well as mononuclear phagocytes and endothelial cells.1–5 The tendency of family history of cardiovascular disease to correlate with enhanced sCD40L plasma levels suggests that genetic factors might contribute to our observation. Although we found no association between sCD40L and C-reactive protein, IL-6, or ICAM-1 levels, the absolute number of subjects with markedly elevated sCD40L was small, and CD40/CD40L-independent mechanisms may well pertain to women who develop cardiovascular complications despite low sCD40L levels. However, our finding suggests that high plasma concentrations of sCD40L reflect aspects of risk distinct from those gauged by other inflammatory markers. Administration of aspirin after the measurement of sCD40L does not appear to attenuate subsequent risk of a cardiovascular event, unlike C-reactive protein.13
In conclusion, these limited prospective data provide evidence that elevated plasma concentrations of sCD40L at baseline may identify certain apparently healthy women at high risk for cardiovascular events, an observation that we believe should stimulate further evaluation of sCD40L as a biomarker for cardiovascular disease.
|
Acknowledgments |
|---|
This study was supported in part by grants from the National Heart, Lung and Blood Institute (HL-34636, HL-56985, HL-58755, and HL-63293). Dr Ridker was further supported by an Established Investigator Award from the American Heart Association and by a Distinguished Clinical Scientist Award from the Doris Duke Charitable Foundation. The authors also acknowledge Karen Williams for editorial assistance.
|
Footnotes |
|---|
*The first 2 authors contributed equally to this work.
Received July 18, 2001; revision received September 13, 2001; accepted September 14, 2001.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Alderson MR, Armitage RJ, Tough TW, et al. CD40 expression by human monocytes: regulation by cytokines and activation of monocytes by the ligand for CD40. J Exp Med. 1993; 178: 669–674.
2. Reul RM, Fang JC, Denton MD, et al. CD40 and CD40 ligand (CD154) are coexpressed on microvessels in vivo in human cardiac allograft rejection. Transplantation. 1997; 64: 1765–1774.[Medline] [Order article via Infotrieve]
3.
Mach F, Schönbeck U, Sukhova GK, et al. Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A. 1997; 94: 1931–1936.
4. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998; 391: 591–594.[Medline] [Order article via Infotrieve]
5. Schönbeck U, Libby P. The CD40/CD154 receptor/ligand dyad. Cell Mol Life Sci. 2001; 58: 4–43.[Medline] [Order article via Infotrieve]
6. Mach F, Schönbeck U, Sukhova GK, et al. Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature. 1998; 394: 200–203.[Medline] [Order article via Infotrieve]
7.
Schönbeck U, Sukhova GK, Shimizu K, et al. Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A. 2000; 97: 7458–7463.
8.
Lutgens E, Cleutjens KB, Heeneman S, et al. Both early and delayed anti-CD40L antibody treatment induces a stable plaque phenotype. Proc Natl Acad Sci U S A. 2000; 97: 7464–7469.
9. Graf D, Muller S, Korthauer U, et al. A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol. 1995; 25: 1749–1754.[Medline] [Order article via Infotrieve]
10.
Aukrust P, Muller F, Ueland T, et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina: possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation. 1999; 100: 614–620.
11. Buring JE, Hennekens CH. The women’s health study: summary of the study design. J Myocard Ischemia. 1992; 4: 19–27.
12.
Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000; 342: 836–843.
13.
Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997; 336: 973–979.
This article has been cited by other articles:
 |
|
 |
|
  C. Antoniades, C. Bakogiannis, D. Tousoulis, A. S. Antonopoulos, and C. Stefanadis The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J. Am. Coll. Cardiol., August 18, 2009; 54(8): 669 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 U. Hanusch-Enserer, G. Zorn, J. Wojta, C. W. Kopp, R. Prager, W. Koenig, M. Schillinger, M. Roden, and K. Huber Non-conventional markers of atherosclerosis before and after gastric banding surgery Eur. Heart J., June 2, 2009; 30(12): 1516 - 1524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Plaikner, A. Peer, G. Falkensammer, C. Schmidauer, C. Pechlaner, A. Griesmacher, O. Pachinger, and J. Mair Lack of Association of Soluble CD40 Ligand with the Presence of Acute Myocardial Infarction or Ischemic Stroke in the Emergency Department Clin. Chem., January 1, 2009; 55(1): 175 - 178. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Choudhury, I. Chung, N. Panja, J. Patel, and G. Y. H. Lip Soluble CD40 Ligand, Platelet Surface CD40 Ligand, and Total Platelet CD40 Ligand in Atrial Fibrillation: Relationship to Soluble P-Selectin, Stroke Risk Factors, and Risk Factor Intervention Chest, September 1, 2008; 134(3): 574 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Natal, P. Restituto, C. Inigo, I. Colina, J. Diez, and N. Varo The Proinflammatory Mediator CD40 Ligand Is Increased in the Metabolic Syndrome and Modulated by Adiponectin J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2319 - 2327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. M. Miller and S. P. Duckles Vascular Actions of Estrogens: Functional Implications Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Brili, D. Tousoulis, C. Antoniades, C. Vasiliadou, M. Karali, N. Papageorgiou, N. Ioakeimidis, K. Marinou, E. Stefanadi, and C. Stefanadis Effects of Ramipril on Endothelial Function and the Expression of Proinflammatory Cytokines and Adhesion Molecules in Young Normotensive Subjects With Successfully Repaired Coarctation of Aorta A Randomized Cross-Over Study. J. Am. Coll. Cardiol., February 19, 2008; 51(7): 742 - 749. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. S. Packard and P. Libby Inflammation in Atherosclerosis: From Vascular Biology to Biomarker Discovery and Risk Prediction Clin. Chem., January 1, 2008; 54(1): 24 - 38. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Davi and C. Patrono Platelet Activation and Atherothrombosis N. Engl. J. Med., December 13, 2007; 357(24): 2482 - 2494. [Full Text] [PDF]
|
|
|
|
|
|
A. Choudhury, B. Freestone, J. Patel, and G. Y. H. Lip Relationship of Soluble CD40 Ligand to Vascular Endothelial Growth Factor, Angiopoietins, and Tissue Factor in Atrial Fibrillation: A Link Among Platelet Activation, Angiogenesis, and Thrombosis? Chest, December 1, 2007; 132(6): 1913 - 1919. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Steinhubl, J. J. Badimon, D. L. Bhatt, J.-M. Herbert, and T. F. Luscher Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease Vascular Medicine, May 1, 2007; 12(2): 113 - 122. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Zirlik, U. Bavendiek, P. Libby, L. MacFarlane, N. Gerdes, J. Jagielska, S. Ernst, M. Aikawa, H. Nakano, E. Tsitsikov, et al. TRAF-1, -2, -3, -5, and -6 Are Induced in Atherosclerotic Plaques and Differentially Mediate Proinflammatory Functions of CD40L in Endothelial Cells Arterioscler Thromb Vasc Biol, May 1, 2007; 27(5): 1101 - 1107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zirlik, C. Maier, N. Gerdes, L. MacFarlane, J. Soosairajah, U. Bavendiek, I. Ahrens, S. Ernst, N. Bassler, A. Missiou, et al. CD40 Ligand Mediates Inflammation Independently of CD40 by Interaction With Mac-1 Circulation, March 27, 2007; 115(12): 1571 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Kosuge, J.-i. Suzuki, G. Haraguchi, N. Koga, Y. Maejima, M. Inobe, M. Isobe, and T. Uede Critical Role of Inducible Costimulator Signaling in the Development of Arteriosclerosis Arterioscler Thromb Vasc Biol, December 1, 2006; 26(12): 2660 - 2665. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Alessandri, P. Pignatelli, L. Loffredo, L. Lenti, M. Del Ben, R. Carnevale, A. Perrone, D. Ferro, F. Angelico, and F. Violi Alpha-linolenic acid-rich wheat germ oil decreases oxidative stress and CD40 ligand in patients with mild hypercholesterolemia. Arterioscler Thromb Vasc Biol, November 1, 2006; 26(11): 2577 - 2578. [Full Text] [PDF]
|
|
|
|
 |
|
 M McMahon, J Grossman, W Chen, and B H Hahn Inflammation and the pathogenesis of atherosclerosis in systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 59 - 69. [Abstract] [PDF]
|
|
|
|
|
|
P. Libby and P. M. Ridker Inflammation and Atherothrombosis: From Population Biology and Bench Research to Clinical Practice J. Am. Coll. Cardiol., October 27, 2006; 48(9_Suppl_A): A33 - A46. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Geraldes, S. Gagnon, S. Hadjadj, Y. Merhi, M. G. Sirois, I. Cloutier, and J.-F. Tanguay Estradiol blocks the induction of CD40 and CD40L expression on endothelial cells and prevents neutrophil adhesion: An ER{alpha}-mediated pathway Cardiovasc Res, August 1, 2006; 71(3): 566 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Circulation, June 20, 2006; 113(24): e873 - e923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. B. Goldstein, R. Adams, M. J. Alberts, L. J. Appel, L. M. Brass, C. D. Bushnell, A. Culebras, T. J. DeGraba, P. B. Gorelick, J. R. Guyton, et al. Primary Prevention of Ischemic Stroke: A Guideline From the American Heart Association/American Stroke Association Stroke Council: Cosponsored by the Atherosclerotic Peripheral Vascular Disease Interdisciplinary Working Group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research Interdisciplinary Working Group: The American Academy of Neurology affirms the value of this guideline. Stroke, June 1, 2006; 37(6): 1583 - 1633. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Vasan Biomarkers of Cardiovascular Disease: Molecular Basis and Practical Considerations Circulation, May 16, 2006; 113(19): 2335 - 2362. [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kobayashi, Y. Nishimura, T. Shimada, S. Yoshimura, Y. Funada, M. Satouchi, and M. Yokoyama Effect of Continuous Positive Airway Pressure on Soluble CD40 Ligand in Patients With Obstructive Sleep Apnea Syndrome Chest, March 1, 2006; 129(3): 632 - 637. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Danese, M. Sans, F. Scaldaferri, A. Sgambato, S. Rutella, A. Cittadini, J. M. Pique, J. Panes, J. A. Katz, A. Gasbarrini, et al. TNF-{alpha} Blockade Down-Regulates the CD40/CD40L Pathway in the Mucosal Microcirculation: A Novel Anti-Inflammatory Mechanism of Infliximab in Crohn's Disease J. Immunol., February 15, 2006; 176(4): 2617 - 2624. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Santilli, G. Davi, A. Consoli, F. Cipollone, A. Mezzetti, A. Falco, T. Taraborelli, E. Devangelio, G. Ciabattoni, S. Basili, et al. Thromboxane-Dependent CD40 Ligand Release in Type 2 Diabetes Mellitus J. Am. Coll. Cardiol., January 17, 2006; 47(2): 391 - 397. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. W Clarke, N. C Ward, J. H. Wu, J. M Hodgson, I. B Puddey, and K. D Croft Supplementation with mixed tocopherols increases serum and blood cell {gamma}-tocopherol but does not alter biomarkers of platelet activation in subjects with type 2 diabetes Am. J. Clinical Nutrition, January 1, 2006; 83(1): 95 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Freedman Molecular Regulation of Platelet-Dependent Thrombosis Circulation, October 25, 2005; 112(17): 2725 - 2734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Davis and M.-H. Zou CD40 Ligand-Dependent Tyrosine Nitration of Prostacyclin Synthase In Vivo Circulation, October 4, 2005; 112(14): 2184 - 2192. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. de Lemos, A. Zirlik, U. Schonbeck, N. Varo, S. A. Murphy, A. Khera, D. K. McGuire, G. Stanek, H. S. Lo, R. Nuzzo, et al. Associations Between Soluble CD40 Ligand, Atherosclerosis Risk Factors, and Subclinical Atherosclerosis: Results from the Dallas Heart Study Arterioscler Thromb Vasc Biol, October 1, 2005; 25(10): 2192 - 2196. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Fuster, P. R. Moreno, Z. A. Fayad, R. Corti, and J. J. Badimon Atherothrombosis and High-Risk Plaque: Part I: Evolving Concepts J. Am. Coll. Cardiol., September 20, 2005; 46(6): 937 - 954. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schomig, C. Schmitt, A. Dibra, J. Mehilli, C. Volmer, H. Schuhlen, J. Dirschinger, F. Dotzer, J. M. ten Berg, F.-J. Neumann, et al. One year outcomes with abciximab vs. placebo during percutaneous coronary intervention after pre-treatment with clopidogrel Eur. Heart J., July 2, 2005; 26(14): 1379 - 1384. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-C. Chen, H.-W. Chang, C.-J. Wu, C.-H. Yang, W. C. Hung, K.-H. Yeh, and M. Fu Percutaneous Transluminal Mitral Valvuloplasty Reduces Circulating Soluble CD40 Ligand in Rheumatic Mitral Stenosis Chest, July 1, 2005; 128(1): 36 - 41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. A. Ajijola, P. J. Goldschmidt-Clermont, and L. L. Satterwhite CD40 Ligand: Not Bad to the Bone (Marrow), After All Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1088 - 1090. [Full Text] [PDF]
|
|
|
|
|
|
A. M. Halldorsdottir, J. Stoker, R. Porche-Sorbet, and C. S. Eby Soluble CD40 Ligand Measurement Inaccuracies Attributable to Specimen Type, Processing Time, and ELISA Method Clin. Chem., June 1, 2005; 51(6): 1054 - 1057. [Full Text] [PDF]
|
|
|
|
|
|
U. Bavendiek, A. Zirlik, S. LaClair, L. MacFarlane, P. Libby, and U. Schonbeck Atherogenesis in Mice Does Not Require CD40 Ligand From Bone Marrow-Derived Cells Arterioscler Thromb Vasc Biol, June 1, 2005; 25(6): 1244 - 1249. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Varo, P. Libby, R. Nuzzo, J. Italiano, A. Doria, and U. Schonbeck Elevated release of sCD40L from platelets of diabetic patients by thrombin, glucose and advanced glycation end products Diabetes and Vascular Disease Research, May 1, 2005; 2(2): 81 - 87. [Abstract] [PDF]
|
|
|
|
|
|
F. S. Apple, A. H.B. Wu, J. Mair, J. Ravkilde, M. Panteghini, J. Tate, F. Pagani, R. H. Christenson, M. Mockel, O. Danne, et al. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome Clin. Chem., May 1, 2005; 51(5): 810 - 824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. K. MacCallum Markers of Hemostasis and Systemic Inflammation in Heart Disease and Atherosclerosis in Smokers Proceedings of the ATS, April 1, 2005; 2(1): 34 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Novo, S. Basili, R. Tantillo, A. Falco, V. Davi, G. Novo, E. Corrado, and G. Davi Soluble CD40L and Cardiovascular Risk in Asymptomatic Low-Grade Carotid Stenosis Stroke, March 1, 2005; 36(3): 673 - 675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Anderson Candidate-based proteomics in the search for biomarkers of cardiovascular disease J. Physiol., February 15, 2005; 563(1): 23 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Tedgui The role of inflammation in atherothrombosis: implications for clinical practice Vascular Medicine, February 1, 2005; 10(1): 45 - 53. [Abstract] [PDF]
|
|
|
|
|
|
V. Sanguigni, P. Pignatelli, L. Lenti, D. Ferro, A. Bellia, R. Carnevale, M. Tesauro, R. Sorge, R. Lauro, and F. Violi Short-Term Treatment With Atorvastatin Reduces Platelet CD40 Ligand and Thrombin Generation in Hypercholesterolemic Patients Circulation, February 1, 2005; 111(4): 412 - 419. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Sanguigni, D. Ferro, P. Pignatelli, M. Del Ben, T. Nadia, M. Saliola, R. Sorge, and F. Violi CD40 ligand enhances monocyte tissue factor expression and thrombin generation via oxidative stress in patients with hypercholesterolemia J. Am. Coll. Cardiol., January 4, 2005; 45(1): 35 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Michelson Platelet Function Testing in Cardiovascular Diseases Circulation, November 9, 2004; 110(19): e489 - e493. [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Chilton Pathophysiology of Coronary Heart Disease: A Brief Review J Am Osteopath Assoc, September 1, 2004; 104(9_suppl): 5S - 8S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Akbiyik, D. M. Ray, K. F. Gettings, N. Blumberg, C. W. Francis, and R. P. Phipps Human bone marrow megakaryocytes and platelets express PPAR{gamma}, and PPAR{gamma} agonists blunt platelet release of CD40 ligand and thromboxanes Blood, September 1, 2004; 104(5): 1361 - 1368. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kinlay, G. G. Schwartz, A. G. Olsson, N. Rifai, W. J. Sasiela, M. Szarek, P. Ganz, P. Libby, and for the Myocardial Ischemia Reduction with Aggress Effect of Atorvastatin on Risk of Recurrent Cardiovascular Events After an Acute Coronary Syndrome Associated With High Soluble CD40 Ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Circulation, July 27, 2004; 110(4): 386 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M Ridker, N. J. Brown, D. E. Vaughan, D. G. Harrison, and J. L. Mehta Established and Emerging Plasma Biomarkers in the Prediction of First Atherothrombotic Events Circulation, June 29, 2004; 109(25_suppl_1): IV-6 - IV-19. [Full Text] [PDF]
|
|
|
|
|
|
M. I. Furman, L. A. Krueger, M. D. Linden, M. R. Barnard, A. L. Frelinger III, and A. D. Michelson Release of soluble CD40L from platelets is regulated by glycoprotein IIb/IIIa and actin polymerization J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2319 - 2325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Aukrust, J. K. Damas, and N. O. Solum Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation? J. Am. Coll. Cardiol., June 16, 2004; 43(12): 2326 - 2328. [Full Text] [PDF]
|
|
|
|
|
|
H. S. Lim, A. D. Blann, and G. Y.H. Lip Soluble CD40 Ligand, Soluble P-Selectin, Interleukin-6, and Tissue Factor in Diabetes Mellitus: Relationships to Cardiovascular Disease and Risk Factor Intervention Circulation, June 1, 2004; 109(21): 2524 - 2528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. T. Willerson and P. M. Ridker Inflammation as a Cardiovascular Risk Factor Circulation, June 1, 2004; 109(21_suppl_1): II-2 - II-10. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schonbeck and P. Libby Inflammation, Immunity, and HMG-CoA Reductase Inhibitors: Statins as Antiinflammatory Agents? Circulation, June 1, 2004; 109(21_suppl_1): II-18 - II-26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Targher and G. Zoppini Soluble CD40L in Young Type 1 Diabetic Individuals Without Clinical Microvascular and Macrovascular Complications Diabetes Care, May 1, 2004; 27(5): 1236 - 1237. [Full Text] [PDF]
|
|
|
|
 |
|
 D. N. Granger, T. Vowinkel, and T. Petnehazy Modulation of the Inflammatory Response in Cardiovascular Disease Hypertension, May 1, 2004; 43(5): 924 - 931. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.A. Harding, J. Sarma, D.H. Josephs, N.L. Cruden, J.N. Din, P.J. Twomey, K.A.A. Fox, and D.E. Newby Upregulation of the CD40/CD40 Ligand Dyad and Platelet-Monocyte Aggregation in Cigarette Smokers Circulation, April 27, 2004; 109(16): 1926 - 1929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Roman, B.-A. Shanker, A. Davis, M. D. Lockshin, L. Sammaritano, R. Simantov, M. K. Crow, J. E. Schwartz, S. A. Paget, R. B. Devereux, et al. Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus N. Engl. J. Med., December 18, 2003; 349(25): 2399 - 2406. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cipollone, C. Ferri, G. Desideri, L. Paloscia, G. Materazzo, M. Mascellanti, M. Fazia, A. Iezzi, C. Cuccurullo, B. Pini, et al. Preprocedural Level of Soluble CD40L Is Predictive of Enhanced Inflammatory Response and Restenosis After Coronary Angioplasty Circulation, December 2, 2003; 108(22): 2776 - 2782. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Szmitko, C.-H. Wang, R. D. Weisel, J. R. de Almeida, T. J. Anderson, and S. Verma New Markers of Inflammation and Endothelial Cell Activation: Part I Circulation, October 21, 2003; 108(16): 1917 - 1923. [Full Text] [PDF]
|
|
|
|
 |
|
 K. S. S. Prasad, P. Andre, M. He, M. Bao, J. Manganello, and D. R. Phillips Soluble CD40 ligand induces {beta}3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling PNAS, October 14, 2003; 100(21): 12367 - 12371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Naghavi, P. Libby, E. Falk, S. W. Casscells, S. Litovsky, J. Rumberger, J. J. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, et al. From Vulnerable Plaque to Vulnerable Patient: A Call for New Definitions and Risk Assessment Strategies: Part II Circulation, October 14, 2003; 108(15): 1772 - 1778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S Danese, J A Katz, S Saibeni, A Papa, A Gasbarrini, M Vecchi, and C Fiocchi Activated platelets are the source of elevated levels of soluble CD40 ligand in the circulation of inflammatory bowel disease patients Gut, October 1, 2003; 52(10): 1435 - 1441. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Varo, J. A. de Lemos, P. Libby, D. A. Morrow, S. A. Murphy, R. Nuzzo, C. M. Gibson, C. P. Cannon, E. Braunwald, and U. Schonbeck Soluble CD40L: Risk Prediction After Acute Coronary Syndromes Circulation, September 2, 2003; 108(9): 1049 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bereczki, E. Nagy, A. Pal, M. T. Magyar, J. Balla, G. J. Blake, R. J. Ostfeld, E. K. Yucel, N. Varo, U. Schonbeck, et al. Should Soluble CD40 Ligand Be Measured From Serum or Plasma Samples? * Arterioscler Thromb Vasc Biol, June 12, 2003; 23(6): 1129 - 1130. [Full Text] [PDF]
|
|
|
|
|
|
N. Varo, D. Vicent, P. Libby, R. Nuzzo, A. L. Calle-Pascual, M. R. Bernal, A. Fernandez-Cruz, A. Veves, P. Jarolim, J. J. Varo, et al. Elevated Plasma Levels of the Atherogenic Mediator Soluble CD40 Ligand in Diabetic Patients: A Novel Target of Thiazolidinediones Circulation, June 3, 2003; 107(21): 2664 - 2669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Freedman CD40-CD40L and Platelet Function: Beyond Hemostasis Circ. Res., May 16, 2003; 92(9): 944 - 946. [Full Text] [PDF]
|
|
|
|
|
|
N. Marx, A. Imhof, J. Froehlich, L. Siam, J. Ittner, G. Wierse, A. Schmidt, W. Maerz, V. Hombach, and W. Koenig Effect of Rosiglitazone Treatment on Soluble CD40L in Patients With Type 2 Diabetes and Coronary Artery Disease Circulation, April 22, 2003; 107(15): 1954 - 1957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Heeschen, S. Dimmeler, C. W. Hamm, M. J. van den Brand, E. Boersma, A. M. Zeiher, M. L. Simoons, and the CAPTURE Study Investigators Soluble CD40 Ligand in Acute Coronary Syndromes N. Engl. J. Med., March 20, 2003; 348(12): 1104 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Freedman CD40 Ligand -- Assessing Risk Instead of Damage? N. Engl. J. Med., March 20, 2003; 348(12): 1163 - 1165. [Full Text] [PDF]
|
|
|
|
|
|
L. Nannizzi-Alaimo, V. L. Alves, and D. R. Phillips Inhibitory Effects of Glycoprotein IIb/IIIa Antagonists and Aspirin on the Release of Soluble CD40 Ligand During Platelet Stimulation Circulation, March 4, 2003; 107(8): 1123 - 1128. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. G. Semb, S. van Wissen, T. Ueland, T. Smilde, T. Waehre, M. D. Tripp, S. S. Froland, J. J. P. Kastelein, L. Gullestad, T. R. Pedersen, et al. Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy J. Am. Coll. Cardiol., January 15, 2003; 41(2): 275 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. J. Blake, R. J. Ostfeld, E. K. Yucel, N. Varo, U. Schonbeck, M. A. Blake, M. Gerhard, P. M. Ridker, P. Libby, and R. T. Lee Soluble CD40 Ligand Levels Indicate Lipid Accumulation in Carotid Atheroma: An In Vivo Study With High-Resolution MRI Arterioscler Thromb Vasc Biol, January 1, 2003; 23(1): e11 - 14. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schonbeck, N. Gerdes, N. Varo, R. S. Reynolds, D. B. Horton, U. Bavendiek, L. Robbie, P. Ganz, S. Kinlay, and P. Libby Oxidized Low-Density Lipoprotein Augments and 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors Limit CD40 and CD40L Expression in Human Vascular Cells Circulation, December 3, 2002; 106(23): 2888 - 2893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Andre, L. Nannizzi-Alaimo, S. K. Prasad, and D. R. Phillips Platelet-Derived CD40L: The Switch-Hitting Player of Cardiovascular Disease Circulation, August 20, 2002; 106(8): 896 - 899. [Full Text] [PDF]
|
|
|
|
|
|
C. Urbich, E. Dernbach, A. Aicher, A. M. Zeiher, and S. Dimmeler CD40 Ligand Inhibits Endothelial Cell Migration by Increasing Production of Endothelial Reactive Oxygen Species Circulation, August 20, 2002; 106(8): 981 - 986. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cipollone, A. Mezzetti, E. Porreca, C. Di Febbo, M. Nutini, M. Fazia, A. Falco, F. Cuccurullo, and G. Davi Association Between Enhanced Soluble CD40L and Prothrombotic State in Hypercholesterolemia: Effects of Statin Therapy Circulation, July 23, 2002; 106(4): 399 - 402. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Bhatt and E. J. Topol Need to Test the Arterial Inflammation Hypothesis Circulation, July 2, 2002; 106(1): 136 - 140. [Full Text] [PDF]
|
|
|
|
|
|
L. Nannizzi-Alaimo, M. H. Rubenstein, V. L. Alves, G. Y. Leong, D. R. Phillips, and H. K. Gold Cardiopulmonary Bypass Induces Release of Soluble CD40 Ligand Circulation, June 18, 2002; 105(24): 2849 - 2854. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Schonbeck and P. Libby CD40 Signaling and Plaque Instability Circ. Res., December 7, 2001; 89(12): 1092 - 1103. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||